Relative Contributions of Red Cell Catabolism and Dietary Absorption to Fetal Iron Accretion During Pregnancy
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Iron Deficiency Anemia, Anemia |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 15 - 35 |
| Updated: | 2/6/2019 |
| Start Date: | April 2012 |
| End Date: | December 2019 |
The two specific aims of this study are 1) to assess the relative contributions of two major
maternal iron sources (i.e. dietary iron intake and red cell catabolism) at supplying iron to
the fetus, and 2) to determine the impact of maternal and fetal iron status on placental
transfer of these two iron sources in pregnant women and adolescents during the last
trimester of pregnancy.
maternal iron sources (i.e. dietary iron intake and red cell catabolism) at supplying iron to
the fetus, and 2) to determine the impact of maternal and fetal iron status on placental
transfer of these two iron sources in pregnant women and adolescents during the last
trimester of pregnancy.
Pregnant women and adolescents (n=24) will be recruited when entering prenatal care. They
will be invited to participate in a longitudinal study comparing the relative contribution of
the two major maternal iron sources, i.e. maternal dietary iron intake and maternal red blood
cell iron recycling, to fetal iron accretion during pregnancy. At about 15 weeks of
gestation, participants will consume an oral dose of a stable iron isotope (57Fe as ferrous
sulfate) to enrich their red blood cells (RBCs) with 57Fe. Maternal blood samples will be
collected at 4 times during pregnancy to monitor changes in blood 57Fe concentrations. In the
third trimester of pregnancy, women will consume a dose of a different iron isotope (58Fe as
ferrous sulfate) as dietary nonheme iron. Cord blood samples and placental tissue will be
obtained at delivery to determine how much of the dietary iron (58Fe) and RBC iron (57Fe) was
transferred to the fetus and how much of each isotope was retained in the placenta. Placenta
tissue samples will also be used to assess placental expression of iron transporters in
relation to the amount of each iron isotopes transferred to the fetus. Circulating iron
status indicators and regulators will be measured in all maternal and cord blood samples to
examine the effect of iron status on placental transfer of iron derived from the diet vs. RBC
during pregnancy.
will be invited to participate in a longitudinal study comparing the relative contribution of
the two major maternal iron sources, i.e. maternal dietary iron intake and maternal red blood
cell iron recycling, to fetal iron accretion during pregnancy. At about 15 weeks of
gestation, participants will consume an oral dose of a stable iron isotope (57Fe as ferrous
sulfate) to enrich their red blood cells (RBCs) with 57Fe. Maternal blood samples will be
collected at 4 times during pregnancy to monitor changes in blood 57Fe concentrations. In the
third trimester of pregnancy, women will consume a dose of a different iron isotope (58Fe as
ferrous sulfate) as dietary nonheme iron. Cord blood samples and placental tissue will be
obtained at delivery to determine how much of the dietary iron (58Fe) and RBC iron (57Fe) was
transferred to the fetus and how much of each isotope was retained in the placenta. Placenta
tissue samples will also be used to assess placental expression of iron transporters in
relation to the amount of each iron isotopes transferred to the fetus. Circulating iron
status indicators and regulators will be measured in all maternal and cord blood samples to
examine the effect of iron status on placental transfer of iron derived from the diet vs. RBC
during pregnancy.
Inclusion Criteria:
- Singleton pregnancy
- Non-smoker
- No pre-existing medical complications (such as HIV-infection, eating disorders,
hemoglobinopathies, malabsorption diseases, steroid use, substance abuse history, or
taking medications known to influence iron homeostasis)
Exclusion Criteria:
- Complicated pregnancy (including gestational diabetes, pregnancy-induced hypertension,
or preeclampsia)
- Individuals been previously treated for lead exposure, or those that have been
identified as having elevated blood lead concentrations during childhood, will be
excluded from the study
We found this trial at
1
site
Click here to add this to my saved trials
